Introduction to Genetic Technologies' groundbreaking development

Genetic Technologies Limited (ASX: $GTG) has announced the development of its most advanced risk assessment test for serious diseases, expanding on the success of the Comprehensive Hereditary Breast and Ovarian Cancer (HBOC) test. The new test, named GeneType, will include over 200 high penetrant genes to unlock the hereditary disease risk associated with the most common cancers, cardiovascular disease, and type 2 diabetes.

Executive commentary on the groundbreaking innovation

GTG's CEO Simon Morriss expressed, 'As pioneers in risk assessment testing, we are thrilled to introduce our latest GeneType Comprehensive Risk Assessment Test. This test empowers individuals to take control of their health and enables healthcare professionals to deliver truly personalized care, resulting in a significant improvement in patient outcomes.'

Summary of Genetic Technologies' latest development and outlook

Genetic Technologies' latest innovation, the GeneType Comprehensive Risk Assessment Test, represents a significant leap forward in personalized preventative healthcare. With over 200 high penetrant genes, the test provides a comprehensive evaluation of an individual's genetic predisposition to serious diseases, going beyond family history. The company's commitment to advancing genetic diagnostics aligns with its vision of tailored healthcare for everyone's unique genetic makeup. The announcement reflects the company's ambition to revolutionize personalized healthcare and tap into the growing demand for comprehensive genetic risk assessments, particularly in the United States healthcare market. This development marks a significant step towards realizing the company's vision, offering a transformative tool for healthcare providers and their patients.